Successful first commercial fermentation run

28,000 L scale commercial fermentation completed with performance exceeding expectations, laying the foundations for a reliable and scalable commercial supply chain for customers

Read More

Roy Lipski, Creo CEO on the Purpose Driven Entrepreneur Podcast


Creo CEO Roy Lipski sat down with Timmy Bauer on The Purpose Driven Entrepreneur to discuss the benefits of biosynthesis, and how the practice can promote environmentally conscious production methods.

Read More

Minor cannabinoids show large potential


Minor cannabinoids offer a “huge opportunity” within the wellness category…it’s going to be like multivitamins: Cannabinoids are going to be part of our normal routine.

Read More

Creo granted foundational patent for production of cannabinoids

Creo granted foundational patent covering advantaged method of producing GPP, an essential precursor for all cannabinoids production in fermentation.

Read More

Joel Cherry joins Creo as CTO

Dr Joel Cherry joins Creo as Chief Technology Officer. Joel, formerly President of Research and Development at Amyris, brings exceptional technical expertise and industry experience.

Read More

Biotechs are betting millions on unlocking the $115 billion synthetic-cannabis market


A handful of biotechs are raising and spending millions in a bet that they don't need to grow finicky cannabis plants to produce the valuable compounds they contain.

Read More

Interview with Eitan Popper, Strategic Advisor, Creo


Eitan Popper, Strategic Advisor, Creo talks about his start in cannabis, possibilities for the future, intellectual property, and Florida’s framework

Read More

Is the mainstream ready?


As more data unlocks the power of the endocannabinoid system [in the human body], we are discovering increased opportunities from minor cannabinoids such as CBG…

Read More

David Beckham backs biosynthesized cannabinoids


A skin care company backed by David Beckham that plans to use biosynthesized cannabinoids exclusively is set to IPO on the London Stock Exchange.

Read More

Successful 12,500-liter scale demo

Creo becomes first company to achieve demo scale production of rare cannabinoid CBGA.

Read More

Creo set to disrupt with proprietary process

Creo, an ingredient company with a platform for producing rare cannabinoids, such as CBG, announces its official launch.

Read More

Creo announces collaboration with Fift & Root and Joiya


Creo announces collaboration with Fifth & Root and Joiya for skincare products using their proprietary bio-CBG

Read More

The cannabinoid revolution is coming


Cannabinoids, while still underexplored, are powerful and diverse substances. But it’s a unique process for producing them that will truly propel them onto centerstage.

Read More

This is the next CBD (cannabidiol)


From biosynthesis to traditional flower, cannabis companies are increasingly focusing on cannabigerol (CBG), a cannabinoid with potent antimicrobial properties.

Read More

How Creo is building a brand


San Diego-based Creo, led by Cambridge-trained scientist and company CEO Roy Lipski, has developed a powerful method of producing rare cannabinoids without using any plant material.

Read More

Cannabis career watch


Creo welcomed MedReleaf Corp. co-founder and former president Eitan Popper as an investor and strategic adviser. 

Read More

Cannabis movers & shakers


Creo welcomes Eitan Popper as investor and adviser.

Read More

Rare cannabinoids are coming


Poll found CBG is best known of the minor cannabinoids. A significant number of respondents viewed minor cannabinoids as having the most growth potential.

Read More

How CBG may revolutionize the cannabis industry as ‘The next big thing’


Cannabigerol (CBG), a once rare, non-psychoactive cannabinoid, has recently gained momentum. Is it worth the hype?

Read More

Move over CBD: rare cannabinoids shaking up cannabis and hemp products


Since the Farm Bill…startups have been looking to capitalize on new compounds and technologies that may just leave CBD in the dust.

Read More

Frequently asked questions

Creo is an ingredient company that produces rare and novel cannabinoids using the age-old natural process of fermentation, coupled with cutting-edge technological innovation. Creo has a platform for producing cannabinoids as ingredients developed exclusively with its joint venture partner, biotech industry leader Genomatica. Creo’s partner has successfully commercialized fermentation-based processes for plastics, cosmetics and apparel. Creo has the technology to deliver a reliable, high-quality and consistent supply of cannabinoid ingredients at commercial scale.

Creo was formed and continues to be based in the US, with headquarters in Southern California.

Creo’s mission is to enable the creation of cannabinoid products that help people everywhere while doing less harm to the planet.

Creo’s brand is built on three core pillars: sustainable innovation, access to abundance and being a trusted partner to customers. Creo makes its cannabinoid ingredients using one of the world’s oldest natural processes - fermentation. Fermentation requires less water, energy and land than the plant-based approaches typically used to extract cannabinoid ingredients. This gives Creo the ability to support the development of innovative new products without causing unnecessary harm to the planet. Creo’s ingredients are of the very highest quality, containing none of the contaminants often associated with plant-derived ingredients.

Cannabinoids are molecules that interact with the body’s endocannabinoid system (ECS). Phytocannabinoids are those cannabinoids that occur naturally in plants, most commonly the cannabis plant. THC and CBD are the most common phytocannabinoids but there are over 100 additional phytocannabinoids that have been identified. The body also produces its own cannabinoids known as endocannabinoids.

The endocannabinoid system (ECS) within the human body is made up of cannabinoid receptors and endocannabinoids. The receptors are located throughout the body including in the brain, nervous system, skin, immune cells, bone, fat tissue, blood vessels and various organs. The ECS is involved in the regulation of pain, stress, inflammation, appetite, energy, cardiovascular function, reward, sleep and other processes.

CBG, sometimes called the “mother cannabinoid” or “skin cannabinoid,” is the parent molecule from which other cannabinoids are made in the cannabis plant. But since it’s mostly converted into other cannabinoids, such as THC and CBD, very little of it remains intact in the plant (typically <0.5% by weight). Due to its scarcity, up until now, customers and patients have struggled to access the benefits of this important non-intoxicating cannabinoid. Plant cannabinoids are naturally produced in the acid form. Prior to consumption, they are typically converted into their non-acid form (“decarboxylated”) by heating. In this way, CBG is made from CBGA.

Scientific research

There is a growing body of exciting scientific research into CBG, both on its own as well as in combination with other cannabinoids. Areas of research include:

  • Antibacterial (e.g. MRSA, dental plaque)
  • Dry skin
  • Skin inflammation
  • GI inflammation
  • Neuroinflammation and neurodegeneration
  • Insulin resistance
  • Ocular tension
  • Loss of appetite
  • Mood disorders
  • Neuropathic pain

Plant extraction presents a number of challenges and uses large amounts of land, water and often electricity. Additionally:

  • Plant extracts have variable consistency
  • Cultivated plants are prone to contamination and impurities
  • Presence of THC creates regulatory complications
  • Plant extraction is impractical and expensive for rarer cannabinoids
  • Only seasonal availability

The process Creo has developed provides pure, consistent, single molecules that it can produce at scale, contaminant free, with a smaller environmental footprint all year round.

No. Through Creo’s fermentation process it produces natural CBG without the use of the cannabis plant.

Yes, there are more than 100 cannabinoids known in the plant but only two are currently being actively exploited (THC & CBD). Creo specializes in producing a wide variety of rare and novel cannabinoids, beginning with CBG (Cannabigerol).

Creo’s technology and process are patented and proprietary with freedom-to-operate, so customers can rely on Creo to be a trusted supplier.

Creo’s products are manufactured and packaged in an FDA registered food grade facility in the US.

Press kit

Creo, a cannabinoid ingredient company, set to disrupt industry amid launch with proprietary process & technology.


Press kit

Creo, a cannabinoid ingredient company, set to disrupt industry amid launch with proprietary process & technology.


Press kit

Creo, a cannabinoid ingredient company, set to disrupt industry amid launch with proprietary process & technology.